Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively inves...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Mol Sci
Main Authors: Falvella, Felicia Stefania, Caporale, Marta, Cheli, Stefania, Martinetti, Antonia, Berenato, Rosa, Maggi, Claudia, Niger, Monica, Ricchini, Francesca, Bossi, Ilaria, Di Bartolomeo, Maria, Sottotetti, Elisa, Bernardi, Francesca Futura, de Braud, Filippo, Clementi, Emilio, Pietrantonio, Filippo
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2015
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425114/
https://ncbi.nlm.nih.gov/pubmed/25906475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms16048884
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki